Galcanezumab for the prevention of migraine.
| Autor: | Frerichs LM; Department of Neurology, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd. Dallas, TX 75390, USA.; Department of Neurology at Washington University School of Medicine in St. Louis, 660 S. Euclid Ave. Saint Louis, MO 63110, USA., Friedman DI; Department of Neurology, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd. Dallas, TX 75390, USA.; Department of Ophthalmology, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd. Dallas, TX 75390, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Pain management [Pain Manag] 2021 Mar; Vol. 11 (2), pp. 101-112. Date of Electronic Publication: 2020 Dec 09. |
| DOI: | 10.2217/pmt-2020-0030 |
| Abstrakt: | Migraine is a common and disabling disorder affecting approximately 1.02 billion people worldwide. Calcitonin gene-related peptide (CGRP) has been identified as playing an important role in the pathophysiology of migraine and several migraine-specific therapies targeting the CGRP ligand or its receptor have been approved since 2018 for the acute and preventive treatment of migraine. This review focuses on the pharmacology, clinical efficacy and safety/tolerability of galcanezumab, an anti-CGRP monoclonal antibody approved for the prevention of migraine. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|